Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 1, 2000, Pages 15-24

  Singer, F ^a   Mayrhofer, F ^b   Klein, G ^c   Hawel, R ^d   Kollenz, C J ^e,f  

^a Sonderkrankenanstalt Laab im Walde   (Austria)

^b Orthopädische und Neurologische Erkrankungen   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d Rehabilitationszentrum Bad Hofgastein   (Austria)

^e Medical Department Gebro Pharma GmbH   (Austria)

^f Gebro Pharma GmbH   (Austria)

Author keywords

Dexibuprofen; Dose response relationship; NSAID; Osteoarthritis of the hip; Racemic ibuprofen; WOMAC

Indexed keywords

DEXIBUPROFEN;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COXITIS; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENCY; ENANTIOMER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS;

EID: 0033958469     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38015     Document Type: Article

References (48)

1. Adams SS 1987 Non-steroidal anti-inflammatory drugs, plasma half-lives and adverse reactions. Lancet 1987: 1204-1205
2. Altman RD, Hochberg MC 1983 Degenerative joint disease. Clin Rheum Dis 9: 681-693
3. Barner A 1996 Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 25 (Suppl 102): 29-37
4. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW 1988 Validation study of WOMAC: A health status instrument for measuring clinically important patient-relevant outcomes to antirheumatic drug therapy in patients with ostcoarthritis of the hip or knee. J Rheumatol 75: 1833-1840
5. Bellamy N, Buchanan WW 1986 A preliminary evaluation of the dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol 5: 231-241
6. Bollet AJ 1981 Analgesic and anti-inflammatory drugs in the therapy of osteoarthritis. Semin Arthritis Rheum 11 (Suppl 1): 130-132
7. Bombardier C, Tugwell P, Sinclair A, Dok C, Anderson G, Buchanan WW 1982 Preference for end point measures in clinical trials. J Rheumatol 9: 798-801
8. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI 1991 Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325: 87-91
9. Brooks PM, March LA 1995 New insights into osteoarthritis. Med J Aust 163: 367-369
10. Bröll H, Czurda R, Siegmeth W, Smolen J, Thumb N 1996 Praktische Rheumatologie (3. erneuerte Auflage). Blackwell Wissenschaftsverlag, Berlin, pp 263-264
11. Chlud K 1994 Überprüfung der Verträglichkeit von Dexibuprofen an 1400 Patienten unter Bedingungen der täglichen Praxis. Forum Dr Med 16: 76-81
12. Chlud K 1995 Evaluation of tolerance and efficacy of S(+)-ibuprofen (Seractil) in daily practice: a post-marketing-survaillance study in 1400 patients. J Clin Pharmacol 35: 938
13. Colditz GA, Miller NJ, Mosteller F 1988 Measuring gain in the evaluation of medical technology: the probability of a better outcome. Int J Technol Assess Health Care 4: 637-642
14. CPMP/ICH/363/96 1998 ICH Topic E9: Statistical principles for clinical trials. Note for Guidance on statistical principles for clinical trials. Brussels, March 1998
15. Dunnett CW, Gent M 1996 An alternative to the use of two-sided tests in clinical trials. Stat Med 15: 1729-1738
16. Dunnett C, Tamhane AC 1997 Multiple testing to establish superiority/equivalence of a new treatment compared with k standard treatments. Stat Med 16: 2489-2506
17. Eller N, Kollenz CJ, Schiel H, Kikuta C, Mascher H 1998 Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. Int J Clin Pharm Ther 36: 414-417
18. EU-Guideline 3501/91/EEC 1993 "Investigation of chiral active substances, Brussels
19. Evans AM 1996 Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 36: 7-15
20. Garbe E, Röhmel J, Gundert-Remy U 1995 Opinion Paper: Clinical and statistical issues in therapeutical equivalence trials. Eur J Clin Pharmacol 45: 1-7
21. Gabard B, Nirnberger G, Schiel H, Mascher H, Kikuta Ch, Mayer JM 1995 Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. Eur J Clin Pharmacol 48: 505-511
22. Garcia Rodriguez LA, Jick H 1994 Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769-772
23. Hawel R, Klein G, Mitterhuber J, Brugger A 1997 A double-blind study to compare the efficacy and tolerance of dexibuprofen 900 mg with diclofenac sodium in patients with painful osteoarthritis of the knee. Wien Klin Wochenschr 109: 53-59
24. Hawkey C J 1999 COX-2 inhibitors. Lancet 353: 307-314
25. Kantoci D, Wechter WJ 1996 Calculation of inversion half-lives of aryl propionic acid class nonsteroidal antiinflammatory drugs. J Clin Pharmacol 36: 500-504
26. Klein G 1993 Isomerischer Ballast: Pharmakologische Spitzfindigkeit oder medizinischer Fortschritt? Therapiewoche Österreich 8: 652-657
27. Klein G, Hawel R, Wallner H, Kullich W 1994 NSAR-Therapie: Schließt Wirksamkeit Verträglichkeit aus? Klinische Erfahrungen mit dem neuen Antirheumatikum Dexibuprofen. Der Praktische Arzt 48: 307-313
28. Klein G. Neff H, Kullich W, Phleps W, Kollenz CJ 1992 S(+) versus racemic ibuprofen. Lancet 339: 681
29. Kullich W, Wallner H, Klein G 1994 Determination of serum pepsinogen I and II to access the gastroduodenal tolerance of S(+)-ibuprofen. Wien Klin Wochenschr 106: 208-211
30. Lachin J M 1992 Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 11: 1151-70
31. Langmann MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, Murphy M, Vessey MP, Colin-Lones DG 1994 Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet 343: 1075-1078
32. Lawrence JS, Bremner JM, Bier F 1966 Osteoarthrosis: prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 25: 1-24
33. Lee EJD, Williams K, Day R, Graham G, Champion D 1985 Stereo-selective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19: 669-674
34. Leising G, Resel R, Stelzer F, Tasch S, Lanziner A, Hantich G 1996 Physical aspects of dexibuprofen and racemic ibuprofen. J Clin Pharmacol 36: 3S-6S
35. Lequesne M 1982 Clinical Features, diagnostic criteria, functional assessment and radiological classifications of osteoarthritis (excluding the spine). Rheumatology 7: 1-10
36. MacDonald TM, Morant SY, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG 1997 Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 315: 1333-1337
37. Maurer W, Hothorn LA, Lehmacher W 1995 Multiple comparisons in drug clinical and preclinical assays: A priori ordered hypotheses. In: von Vollmar (ed): Testing Principles in Clinical and Preclinical Trials. Fischer, Stuttgart, pp 3-18
38. Max MB, Portenoy RK, Laska EM 1991 Single-dose analgesic comparisons. Adv Pain Res 18: 59
39. National Center for Health Statistics 1966 Prevalence of osteoarthritis in adults by age, sex, race and geographic area: United States 1960-1962. Vital and health statistics. Series 11. No. 15. Government Printing Office, Washington DC
40. Rahlfs VW 1996 Reevaluation of some double-blind randomized studies of dexibuprofen (Seractil): a state-of-the-art overview. J Clin Pharmacol 36: 33S-40S
41. Röhmel J 1998 Therapeutic equivalence investigations: statistical considerations. Stat Med 17: 1703-1714
42. Rudy AC, Knight PM, Craig Brater D, Hall SD 1995 Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. J Pharmacol Exp Ther 273: 88-93
43. Schmidt K 1995 Statistical tests and estimations. Drug Inform J 29: 483-491
44. Schosser R, Quast U 1998 Verdacht auf Nebenwirkungen: Medizinische Überlegungen zur Kausalität. Pharm Ind 3: 185-191
45. Scrip 1998 Meloxicam no better than other NSAIs. Scrip August 2365: 16
46. Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Dick W, Theiler R 1996 Evaluation einer deutschen Version des WOMAC (Western Ontario und McMaster Universities) Arthroseindex. Z Rheumatol 55: 40-49
47. Vane JR, Botting RM 1996 Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 25 (Suppl 102): 9-21
48. Williams K, Day R, Knihinicki R, Duffield A 1986 The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 35: 3403-3405